Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
1.
Arch Immunol Ther Exp (Warsz) ; 39(1-2): 109-15, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1804039

RESUMO

The influence of vit. E treatment on metabolic and bactericidal granulocyte activity in patients with recurrent infections was studied by chemiluminescence and phagocytosis assays. Vit. E serum level was significantly diminished before therapy. Six weeks supplementation with 200-300 mg/day of vit. E resulted in improvement of clinical status and normalisation of alpha-tocopherol serum level. Bactericidal activity of granulocytes was lower in patients than in the respective controls and it slightly rose after vit. E therapy. Before, therapy, patients granulocytes showed metabolic activity above or within the control range. Vit. E treatment increased, had no effect or decreased granulocyte metabolic activity, but never below the control range.


Assuntos
Infecções Bacterianas/tratamento farmacológico , Granulócitos/efeitos dos fármacos , Vitamina E/farmacologia , Adulto , Idoso , Infecções Bacterianas/etiologia , Infecções Bacterianas/fisiopatologia , Atividade Bactericida do Sangue/efeitos dos fármacos , Feminino , Radicais Livres , Granulócitos/fisiologia , Humanos , Medições Luminescentes , Masculino , Pessoa de Meia-Idade , Oxigênio/metabolismo , Recidiva , Vitamina E/sangue , Deficiência de Vitamina E/complicações , Deficiência de Vitamina E/fisiopatologia
2.
Pneumonol Pol ; 57(1): 17-24, 1989 Jan.
Artigo em Polonês | MEDLINE | ID: mdl-2813146

RESUMO

The aim of the study was to determine the therapeutical effectiveness of a new regimen in freshly diagnosed cases of pulmonary tuberculosis. In this model PZA and SM were excluded, but INH administration was prolonged. Instead of INH and RMP a combined drug was given--RIFAMAZIDE (Polfa). Therapy was carried out in three stages: I stage lasting 3 months during which Rifamazide (600 mg RMP, 300 mg INH) and EMB (25 mg per kg b.w.) was given; II stage-during which Rifamazide was given (2 tablets.) for 3 months; III stage--INH monotherapy (300 mg daily) was continued for 6 months. During the first stage all patients were hospitalized at the Institute of Tuberculosis. The second stage was carried out under supervision of an out-patient clinic. During the third stage patients received their INH at their homes. The study group consisted initially of 58 patients, of which 11 were dropped out due to primary resistance, change of therapy, non-compliance, and non-tolerance of drugs. The final evaluation was carried out basing on results from 47 patients. In all patients a negative sputum culture was achieved. In most during the first two months of therapy. All demonstrated improvement in radiological evaluation. In 38 patients the follow-up lasted 2-6 years, in the remaining nine 2 years. Recurrencies were not observed. Good acceptation by the patients of Rifamazide was found.


Assuntos
Isoniazida/administração & dosagem , Tuberculose Pulmonar/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibióticos Antituberculose/uso terapêutico , Esquema de Medicação , Avaliação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA